#62024CC0631Advocate General Opinion on Access to EU COVID-19 Vaccine Purchase Documents
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This opinion deals with how much the European Commission must disclose about its COVID-19 vaccine purchase contracts. The case focuses on two sensitive areas: conflict-of-interest declarations from the negotiation team and contract clauses that protected pharmaceutical companies from certain liability costs. The issue matters for businesses, public bodies, transparency groups, and pharmaceutical companies because it tests the balance between public access to EU documents, personal data protection, and commercial confidentiality. It is not a final court judgment, but it may influence how the Court of Justice rules on future access requests involving high-value public contracts.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Examines whether the Commission lawfully limited access to COVID-19 vaccine purchase documents
- Focuses on disclosure of negotiation team conflict-of-interest declarations
- Reviews whether indemnification clauses for pharmaceutical companies can remain partly confidential
Obligations
What this law requires
EU institutions may refuse public access to documents where disclosure would undermine protection of privacy and integrity of the individual under Article 4(1)(b) of Regulation (EC) No 1049/2001.
EU institutions may refuse public access to documents where disclosure would undermine protection of commercial interests of a natural or legal person under Article 4(2), first indent, of Regulation (EC) No 1049/2001.
Transmission of personal data by EU institutions under Article 9(1)(b) of Regulation (EU) 2018/1725 requires a specific public-interest purpose and must account for prejudice to the data subject’s legitimate interests and proportionality.
The General Court annulled the Commission decisions only insofar as they refused wider access to declarations by COVID-19 vaccine negotiation team members stating that they had no conflict of interests.
The General Court annulled the Commission decisions only insofar as they refused wider access to contractual provisions on indemnification of pharmaceutical undertakings in COVID-19 vaccine purchase agreements.